Fosun Pharmaceutical (02196), a holding subsidiary of Fosun Pharmaceutical Industry, plans to establish a private equity investment fund and transfer 100% equity of Shanghai Clone.

Wisdom Financial News APP, Fosun Pharma (02196) announced that in order to further focus on core business and improve asset operation efficiency, the company's controlling subsidiary Fosun Pharma Industry plans to transfer 100% equity of Shanghai Clone (its main asset is the property located at 1289 Yishan Road, Xuhui District, Shanghai). Accordingly, on September 25, 2025, the company and its controlling subsidiary Fosun Pharma Industry, Shanghai Fushun, Hongyi Tianjin, Zhonghui Life, Hongyuan Holdings, and Honghe Loyuan jointly signed a "Framework Agreement"; on the same day, Fosun Pharma Industry also signed a "Partnership Agreement" with Hongyi Tianjin and Zhonghui Life.